Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy-Reference-Cited by-同舟云学术

Sublobar Resection, Stereotactic Body Radiation Therapy, and Percutaneous Ablation Provide Comparable Outcomes for Lung Metastasis-Directed Therapy

Published:2023-12 Issue: Volume: Page:
ISSN:0012-3692
Container-title:CHEST
language:en
Short-container-title:CHEST

Author:

Gits Hunter C.,Khosravi Flanigan Mitra A.,Kapplinger Jamie D.,Reisenauer Janani S.,Eiken Patrick W.,Breen William G.^ORCID,Vu Linh H.^ORCID,Welch Brian T.,Harmsen William S.,Day Courtney N.,Olivier Kenneth R.,Park Sean S.,Garces Yolanda I.,Hallemeier Christopher L.,Merrell Kenneth W.,Ashman Jonathan B.,Schild Steven E.,Grams Michael P.,Lucido J. John,Shen K. Robert,Cassivi Stephen D.,Wigle Dennis,Nichols Francis C.,Blackmon Shanda,Tapias Luis F.,Callstrom Matthew R.,Owen Dawn

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference53 articles.

1. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial;Brodowicz;Lung Cancer,2006

2. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study;Cappuzzo;Lancet Oncol,2010

3. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study;Ciuleanu;Lancet,2009

4. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer;Paz-Ares;J Clin Oncol,2013

5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating Lung Metastases;CHEST;2024-05

2. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory;Translational Lung Cancer Research;2024-01